Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
Travera Inc
Hoffmann-La Roche
Arvinas Inc.
Jonsson Comprehensive Cancer Center
Amgen
xCures
Zhejiang University
University of Pittsburgh
RenJi Hospital
West China Hospital
Massive Bio, Inc.
Incyte Corporation
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited
Eli Lilly and Company
Celldex Therapeutics
TransThera Sciences (Nanjing), Inc.
Merus B.V.